GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » Cyclically Adjusted Book per Share

Oncotelic Therapeutics (Oncotelic Therapeutics) Cyclically Adjusted Book per Share : $0.49 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Oncotelic Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $0.030. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.49 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Oncotelic Therapeutics's average Cyclically Adjusted Book Growth Rate was -35.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -35.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Oncotelic Therapeutics was 2.20% per year. The lowest was -61.50% per year. And the median was -15.85% per year.

As of today (2024-05-01), Oncotelic Therapeutics's current stock price is $0.03995. Oncotelic Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.49. Oncotelic Therapeutics's Cyclically Adjusted PB Ratio of today is 0.08.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Oncotelic Therapeutics was 0.32. The lowest was 0.01. And the median was 0.02.


Oncotelic Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Oncotelic Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncotelic Therapeutics Cyclically Adjusted Book per Share Chart

Oncotelic Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 1.81 1.18 0.76 0.49

Oncotelic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.70 0.60 0.52 0.49

Competitive Comparison of Oncotelic Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Oncotelic Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncotelic Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oncotelic Therapeutics's Cyclically Adjusted PB Ratio falls into.



Oncotelic Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncotelic Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.03/129.4194*129.4194
=0.030

Current CPI (Dec. 2023) = 129.4194.

Oncotelic Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.560 99.695 2.025
201406 1.686 100.560 2.170
201409 1.525 100.428 1.965
201412 1.401 99.070 1.830
201503 1.338 99.621 1.738
201506 1.223 100.684 1.572
201509 1.094 100.392 1.410
201512 0.955 99.792 1.239
201603 0.837 100.470 1.078
201606 0.709 101.688 0.902
201609 0.594 101.861 0.755
201612 0.471 101.863 0.598
201703 0.331 102.862 0.416
201706 0.192 103.349 0.240
201709 0.066 104.136 0.082
201712 -0.018 104.011 -0.022
201803 -0.041 105.290 -0.050
201806 0.013 106.317 0.016
201809 0.001 106.507 0.001
201812 -0.009 105.998 -0.011
201903 -0.019 107.251 -0.023
201906 0.067 108.070 0.080
201909 0.057 108.329 0.068
201912 0.201 108.420 0.240
202003 0.172 108.902 0.204
202006 0.178 108.767 0.212
202009 0.166 109.815 0.196
202012 0.130 109.897 0.153
202103 0.027 111.754 0.031
202106 0.024 114.631 0.027
202109 0.021 115.734 0.023
202112 0.021 117.630 0.023
202203 0.017 121.301 0.018
202206 0.063 125.017 0.065
202209 0.062 125.227 0.064
202212 0.050 125.222 0.052
202303 0.048 127.348 0.049
202306 0.031 128.729 0.031
202309 0.032 129.860 0.032
202312 0.030 129.419 0.030

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Oncotelic Therapeutics  (OTCPK:OTLC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oncotelic Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.03995/0.49
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Oncotelic Therapeutics was 0.32. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Oncotelic Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Executives
Vuong Trieu officer: CHIEF EXECUTIVE OFFICER 4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund officer: CHIEF BUSINESS OFFICER C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah officer: CHIEF FINANCIAL OFFICER 10 AGUILA, ALISO VIEJO CA 92656
Chulho Park officer: CHIEF TECHNOLOGY OFFICER 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King director
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun 10 percent owner, officer: Chief Medical Officer 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao 10 percent owner 701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang 10 percent owner C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds director C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd director C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar officer: Chief Financial Officer 505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha officer: Controller 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080